Drug intelligence / Profile preview

HIV alphavaccine (multivalent)

Development stage: Preclinical
Lead developer: AlphaVax
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**HIV alphavaccine (multivalent)** is an AlphaVax investigational HIV-1 vaccine based on its proprietary alphavirus replicon-particle platform. The non-propagating RNA particle vector is derived from attenuated Venezuelan equine encephalitis virus and is designed to express multiple HIV antigens, promoting both humoral and cellular immune responses through antigen expression in dendritic cells and lymphatic tissues. The program is described as a multivalent HIV-1 vaccine candidate in development. ([alphavax.com](https://alphavax.com/alphavaccine-applications/))

Other names: HIV vaccine (multivalent)

Beyond the preview

Go deeper on HIV alphavaccine (multivalent).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIV alphavaccine (multivalent).

Explore the full profile